Alex Filicevas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alex Filicevas has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Alessia Cimadamore
Department of Medicine, Institute of Pathological Anatomy, University of Udine, Udine, Italy
1 shared publication- Alexia Iasonos
Memorial Sloan Kettering Cancer Center 4 Department of Epidemiology and Biostatistics New York, New York
1 shared publication - Andrea B. Apolo
National Cancer Institute
1 shared publication - Andrea Necchi
Department of Oncology, Vita-Salute San Raffaele University, Milan, Italy
1 shared publication - Arturo Chiti
Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
1 shared publication - Ashish M. Kamat
Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication
Latest Publications
- 10 November 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (32) , 3536-3544
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer
PURPOSE: The evolving treatment landscape of muscle-invasive bladder cancer (MIBC) increasingly warrants novel trial design to evaluate perioperative strategies aimed at bladder preservation. To establish standardized outcome measures for evaluating organ preservation strategies in MIBC, the International Bladder Cancer Group (IBCG) and the Global Society of Rare Genitourinary Tumors (GSRGT) assembled an international, multidisciplinary consensus panel. METHODS: The IBCG and GSRGT gathered global bladder cancer experts and patient advocates to establish a framework for risk-adapted bladder-sparing treatment approaches for MIBC. Working groups reviewed the literature and developed draft recommendations, which were discussed at a live meeting in December 2024 in Milan. This was followed by voting by the members using a modified Delphi process. Recommendations achieving ≥75% agreement during the meeting were further refined and presented. RESULTS: Clinical complete response (cCR) definition should encompass the absence of high-grade malignancy on pathology and malignant cells on urine cytology and no evidence of local or metastatic disease on cross-sectional imaging. Although cCR remains immature as a primary or coprimary end point in registrational trials, it could serve as a suitable end point in early-phase studies and risk-adapted investigations. Event-free survival (EFS) remains the preferred primary end point as it could reliably capture the durability of clinically meaningful benefit after omittance of surgical consolidation or chemoradiation. Given the composite nature of EFS, events should be prespecified, evaluated in an intention-to-treat approach, and meticulously collected. Continuous assessment of individual patient preferences should begin at the outset of perioperative therapy discussions, with informed decision making prioritized throughout. CONCLUSION: The consensus definition of cCR and the framework presented in this study can serve as a foundation for thorough testing of risk-adapted bladder-sparing treatment paradigms for MIBC.
- 10 November 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (32) , 3536-3544
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer
PURPOSE: The evolving treatment landscape of muscle-invasive bladder cancer (MIBC) increasingly warrants novel trial design to evaluate perioperative strategies aimed at bladder preservation. To establish standardized outcome measures for evaluating organ preservation strategies in MIBC, the International Bladder Cancer Group (IBCG) and the Global Society of Rare Genitourinary Tumors (GSRGT) assembled an international, multidisciplinary consensus panel. METHODS: The IBCG and GSRGT gathered global bladder cancer experts and patient advocates to establish a framework for risk-adapted bladder-sparing treatment approaches for MIBC. Working groups reviewed the literature and developed draft recommendations, which were discussed at a live meeting in December 2024 in Milan. This was followed by voting by the members using a modified Delphi process. Recommendations achieving ≥75% agreement during the meeting were further refined and presented. RESULTS: Clinical complete response (cCR) definition should encompass the absence of high-grade malignancy on pathology and malignant cells on urine cytology and no evidence of local or metastatic disease on cross-sectional imaging. Although cCR remains immature as a primary or coprimary end point in registrational trials, it could serve as a suitable end point in early-phase studies and risk-adapted investigations. Event-free survival (EFS) remains the preferred primary end point as it could reliably capture the durability of clinically meaningful benefit after omittance of surgical consolidation or chemoradiation. Given the composite nature of EFS, events should be prespecified, evaluated in an intention-to-treat approach, and meticulously collected. Continuous assessment of individual patient preferences should begin at the outset of perioperative therapy discussions, with informed decision making prioritized throughout. CONCLUSION: The consensus definition of cCR and the framework presented in this study can serve as a foundation for thorough testing of risk-adapted bladder-sparing treatment paradigms for MIBC.
- 19 August 2025
- Published by Springer Nature in Nature Reviews Urology
- Vol. 23 (1) , 40-49
Urinary bladder cancer needs more attention — recommendations for health care professionals and politicians in the European Union
Cancer is a crucial health priority of the current European Commission and a pillar of a strong European Health Union. However, policy measures targeting cancer in the EU do not approach all types of cancer equally. Bladder cancer is the fifth most common cancer in Europe. Although bladder cancer is associated with one of the highest lifetime costs of any cancer, research funding is among the lowest. This imbalance has led to an alarming stagnation in the availability of diagnostic tools, which negatively affected the prognosis and treatment options for bladder cancer, and resulted in complex pathways for patients. The lack of bladder-cancer awareness drastically hinders early detection. Furthermore, insufficient understanding of gender differences in bladder-cancer symptoms exacerbates the gender gap, leading to worse outcomes for women. After the European elections in 2024 and the learnings from Europe’s Beating Cancer Plan, additional effort is needed to inform the policymakers in Brussels and the Member-State capitals to consider an EU agenda with ambitious policy actions targeting neglected cancers, such as bladder cancer, and close the cancer-care gap by supporting awareness and education and by ensuring access to high-quality diagnostic tools, care and treatment.
- 19 August 2025
- Published by Springer Nature in Nature Reviews Urology
- Vol. 23 (1) , 40-49
Urinary bladder cancer needs more attention — recommendations for health care professionals and politicians in the European Union
Cancer is a crucial health priority of the current European Commission and a pillar of a strong European Health Union. However, policy measures targeting cancer in the EU do not approach all types of cancer equally. Bladder cancer is the fifth most common cancer in Europe. Although bladder cancer is associated with one of the highest lifetime costs of any cancer, research funding is among the lowest. This imbalance has led to an alarming stagnation in the availability of diagnostic tools, which negatively affected the prognosis and treatment options for bladder cancer, and resulted in complex pathways for patients. The lack of bladder-cancer awareness drastically hinders early detection. Furthermore, insufficient understanding of gender differences in bladder-cancer symptoms exacerbates the gender gap, leading to worse outcomes for women. After the European elections in 2024 and the learnings from Europe’s Beating Cancer Plan, additional effort is needed to inform the policymakers in Brussels and the Member-State capitals to consider an EU agenda with ambitious policy actions targeting neglected cancers, such as bladder cancer, and close the cancer-care gap by supporting awareness and education and by ensuring access to high-quality diagnostic tools, care and treatment.